- Home
- SER vs ICCC Comparison
SER vs ICCC Comparison
Compare SER & ICCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SER
- ICCC
- Stock Information
- Founded
- SER 2017
- ICCC 1982
- Country
- SER United States
- ICCC United States
- Employees
- SER N/A
- ICCC N/A
- Industry
- SER Biotechnology: Pharmaceutical Preparations
- ICCC Biotechnology: Pharmaceutical Preparations
- Sector
- SER Health Care
- ICCC Health Care
- Exchange
- SER Nasdaq
- ICCC Nasdaq
- Market Cap
- SER 47.5M
- ICCC 39.2M
- IPO Year
- SER 2018
- ICCC 1987
- Fundamental
- Price
- SER $4.73
- ICCC $5.02
- Analyst Decision
- SER
- ICCC
- Analyst Count
- SER 0
- ICCC 0
- Target Price
- SER N/A
- ICCC N/A
- AVG Volume (30 Days)
- SER 10.3K
- ICCC 4.1K
- Earning Date
- SER 11-12-2024
- ICCC 02-25-2025
- Dividend Yield
- SER N/A
- ICCC N/A
- EPS Growth
- SER N/A
- ICCC N/A
- EPS
- SER N/A
- ICCC N/A
- Revenue
- SER $3,157,500.00
- ICCC $23,838,001.00
- Revenue This Year
- SER N/A
- ICCC N/A
- Revenue Next Year
- SER N/A
- ICCC N/A
- P/E Ratio
- SER N/A
- ICCC N/A
- Revenue Growth
- SER 2454.55
- ICCC 46.37
- 52 Week Low
- SER $3.81
- ICCC $3.34
- 52 Week High
- SER $19.93
- ICCC $5.82
- Technical
- Relative Strength Index (RSI)
- SER 48.48
- ICCC 47.31
- Support Level
- SER $4.80
- ICCC $4.84
- Resistance Level
- SER $5.64
- ICCC $5.25
- Average True Range (ATR)
- SER 0.23
- ICCC 0.27
- MACD
- SER 0.04
- ICCC -0.04
- Stochastic Oscillator
- SER 20.16
- ICCC 27.27
About SER Serina Therapeutics Inc.
Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers.
About ICCC ImmuCell Corporation
ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company operates in two business segment. The Scours segment is dedicated to manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows, which is regulated by the United States Food and Drug Administration (FDA). The company generates the majority of its revenue from the Scours segment.